AZD-2066

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H16ClN5O2
Molecular Weight	381.816
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](OC1=NN=C(N1C)C2=CC=NC=C2)C3=NOC(=C3)C4=CC(Cl)=CC=C4

InChI

InChIKey=SXWHYTICXCLKDG-GFCCVEGCSA-N

InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C19H16ClN5O2
Molecular Weight	381.816
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800027605 | https://www.ncbi.nlm.nih.gov/pubmed/23668965

AstraZeneca was developing AZD-2066, a metabotropic glutamate receptor 5 (mGLUR5) antagonist, for the oral treatment of pain indications (e.g. chronic neuropathic pain and painful diabetic neuropathies), depressive disorders and gastro-oesophageal reflux disease. AZD-2066 had been in phase II clinical trials by AstraZeneca for the treatment of diabetic neuropathic pain and phase I for the treatment of gastrooesophageal reflux disease (GERD). However, this reasearch had being discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Metabotropic glutamate receptor 5 39 Target ID: CHEMBL3227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23668965 \| https://www.ncbi.nlm.nih.gov/pubmed/22469098 \| http://adisinsight.springer.com/drugs/800027605 \| https://www.ncbi.nlm.nih.gov/pubmed/24876235 \| https://www.ncbi.nlm.nih.gov/pubmed/24186263	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Neuropathic pain 26 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24876235 https://clinicaltrials.gov/ct2/show/NCT00939094	Primary	Phase II 1132	Unknown Approved Use Unknown
Gastroesophageal reflux disease 59 Sources: http://adisinsight.springer.com/drugs/800027605 https://clinicaltrials.gov/ct2/show/NCT00813306	Primary	Phase II 1132	Unknown Approved Use Unknown
Major depressive disorder 173 Sources: http://adisinsight.springer.com/drugs/800027605 https://clinicaltrials.gov/ct2/show/NCT01145755	Primary	Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
6 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22469098	13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered:		AZD-2066 blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
Chem Scene	CS-0033120	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0033120
MedChem Express	HY-110255	https://www.medchemexpress.com/search.html?q=HY-110255A&ft=&fa=&fp=
MedChem Express	HY-110255A	https://www.medchemexpress.com/search.html?q=HY-110255A&ft=&fa=&fp=
MolPort	MolPort-042-624-538	https://www.molport.com/shop/molecule-link/MolPort-042-624-538
Molnova	M16678	https://www.molnova.com/en/serch-list.html?keywords=M16678
MuseChem	I003542	https://www.musechem.com/product/I003542.html
MuseChem	I012799	https://www.musechem.com/product/I012799.html
eMolecules	43611808	https://orderbb.emolecules.com/search/#?query=43611808
mcule	MCULE-1403434733	https://mcule.com/MCULE-1403434733/

PubMed

Title	Date	PubMed
The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers.	2012 May	22469098
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.	2013 Aug	23455590
AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects.	2014 Aug	24876235

Patents

Sample Use Guides

In Vivo Use Guide

Treatment of pain: capsule, once daily, 12 mg AZD-2066 day 1-4 and 18 mg AZD2066 day 5-28.

Route of Administration: Oral

In Vitro Use Guide

In vitro inhibition by AZD-2066 was observed for the following CYP: CYP1A2 (IC50=14.3 uM), CYP2B6 (IC50=7.4 uM), CYP2C9 (IC50=4.9 μM), CYP2C19 (IC50=9.6 μM) and CYP2D6 (IC50=15 μM). Inhibition of CYP3A4 was also observed, with 60 and 80 % of inhibition at the highest tested concentration of AZD-2066 (300 uM) with midazolam and testosterone as the probe substrates, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:50:29 GMT 2023` Edited by `admin` on `Sat Dec 16 01:50:29 GMT 2023`
Record UNII	MQ908Y1ZB2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-2066

Common Name

English

AZD 2066 [WHO-DD]

Common Name

English

AZD2066

Common Name

English

PYRIDINE, 4-(5-((1R)-1-(5-(3-CHLOROPHENYL)-3-ISOXAZOLYL)ETHOXY)-4-METHYL-4H-1,2,4-TRIAZOL-3-YL)-

Systematic Name

English

Code System Code Type Description

ChEMBL

CHEMBL3545164